<scp>Comparison of</scp>
            1064
            <scp>nm Q‐switched</scp>
            Nd:
            <scp>YAG laser and Jessner peeling in melasma treatment</scp>

Ertam, İlgen; Onur, Marakli; Oraloğlu, Göktürk; Ecem, Bulut Okut; Ünal, İdil

doi:10.1111/dth.15970

Cited by 1 publication

(1 citation statement)

References 22 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Then, by screening the titles and abstracts, we further eliminated 793 studies. Ultimately, 39 randomized clinical trials 12,18–55 were included in the network meta‐analysis. The flowchart of screening and selection is depicted in Figure 1.…”

Section: Resultsmentioning

confidence: 99%

Efficacy and safety of laser‐related therapy for melasma: A systematic review and network meta‐analysis

Ma,

Gao,

Liu

et al. 2023

J of Cosmetic Dermatology

View full text Add to dashboard Cite

BackgroundMelasma is a prevalent, persistent hyperpigmentation disorder that negatively affects the psychological health of patients. However, the treatment outcome remains unsatisfactory due to the complexity of pathogenesis, recurrence characteristics, and relatively high morbidity.ObjectivesTo compare the performance of laser‐related therapies in improving the melasma area severity index (MASI) score of melasma and the occurrence of adverse effects by network meta‐analysis (NMA).MethodsFrom the inception to November 2022, eligible randomized controlled trials were identified. Two investigators independently searched relevant studies from PUBMED, EMBASE, and the Cochrane Library database.ResultsA total of 39 clinical studies with 1394 participants were eligible for enrollment. For efficacy, the NMA demonstrated that Q‐switched Nd: YAG laser + topical medications (QSND+TM) was superior to Q‐switched Nd:YAG laser (QSND) [MD = −4.21 (−6.80, −1.63)], Er: YAG laser + topical medications (ERYL+TM) [MD = ‐3.52 (−6.84, −0.19)], and picosecond laser + topical medications (PICO+TM) [MD = −4.80 (−9.33, −0.27)]. The microneedling + topical medications (MN+TM) was superior to picosecond laser (PICO) [MD = −5.26 (−10.44, −0.08)] and topical medications (TM) [MD = −5.22 (−9.20, −1.23)]. The top five of the surface under the cumulative ranking curve value (SUCRA) are Q‐switched Nd:YAG laser + topical medications (QSND+TM 85.9%), oral tranexamic acid (oTA 80.1%), microneedling + topical medications (MN+TM 79.7%), Q‐switched Nd:YAG laser + intense pulse light (QSND+IPL 78.9%), and fractional carbon dioxide laser + topical medications (FCDL+TM 70.5%).ConclusionsIn conclusion, the Qs‐Nd:YAG laser with topical medications is the first choice for treating melasma according to the SUCRA value. Among the three treatment modalities, namely MN + TM, PICO, and TM, our recommendation favors MN+TM as the superior choice for enhancing the curative efficacy in melasma. However, the actual clinical choice should also take into account the adverse effects, the skin type of the patient, the duration of the disease, and other relevant factors.

show abstract

Section: Resultsmentioning

confidence: 99%